Renal Carcinoma malady

Wikipedia: Renal cell carcinoma (RCC, also known as hypernephroma) is a kidney cancer that originates in the lining...⁴⁴ more...

MalaCards: Renal Carcinoma, also known as renal cell carcinoma, is related to chromophobe renal cell carcinoma and clear cell renal cell carcinoma. An important gene associated with Renal Carcinoma is RCA1 (renal carcinoma associated 1), and among its related pathways are Signal transduction_PTEN pathway and Actin-Based Motility by Rho Family GTPases. The drugs hydroxyurea and interferon alfa-2a,recombinant and the compounds glucose and threonine have been mentioned in the context of this disorder. Affiliated tissues include brain, kidney and lung, and related mouse phenotypes are craniofacial and endocrine/exocrine gland.

renal carcinoma 7 renal cell carcinoma 43

Diseases related to renal carcinoma by text searches and GeneDecks gene sharing:

(show top 50)    (show all 938)

id	Related Disease	Score	Top Affiliating Genes
1	chromophobe renal cell carcinoma	37.5	PCNA, VIM, VHL, CLDN7, PBRM1, FLCN
2	clear cell renal cell carcinoma	37.3	SETD2, VIM, VHL, VEGFA, MYC, RAF1
3	renal oncocytoma	36.0	PCNA, VIM, VHL, CLDN7, FLCN, FH
4	sarcomatoid renal cell carcinoma	34.8	PCNA, VIM, VEGFA, CDH1, FAS, IFNA2
5	carcinoma	34.6	ZNF608, PIK3CG, KLF6, KLF8, NCOA1, KIF21A
6	nonpapillary renal cell carcinoma	34.6	VHL, CTNNA1, EGFR, ABCG2, TGFA
7	papillary renal carcinoma	34.1	MET, SRSF2, TFE3, PRCC
8	hepatitis	32.4	SELP, CD58, FASLG, FAS, IFNA1, IFNA2
9	hemangioblastoma	31.9	VIM, VHL, VEGFA, VCAM1, KDR, AQP1
10	renal clear cell carcinoma	31.8	SETD2, VIM, VHL, VEGFA, CLDN7, KDR
11	kidney cancer	31.6	VHL, VEGFA, RAF1, KDR, MTOR, FLCN
12	hypercalcemia	31.3	VIM, BMP6, B2M, FGF2, MEN1, IL1B
13	papillary adenoma	31.1	VIM, AMACR, PRCC, OGG1
14	cystic kidney	31.1	VHL, JUN, CCL26, PTK2, EGF, TSC2
15	von hippel-lindau disease	30.6	SETD2, VIM, VHL, VEGFA, RAF1, MEN1
16	chronic lymphocytic leukemia	30.6	BCL10, BCL2, BCR, BAX, XIAP, B2M
17	familial renal cell carcinoma	30.3	VHL, FH, FHIT, DIRC2, RNF139, EGF
18	malignant pleural mesothelioma	30.0	XIAP, MSLN, MET, IFNB1, CALB2, CTNNA1
19	erythrocytosis	29.8	SELP, SETD2, VHL, IGFBP3, IGF1, IFNA1
20	nephroblastoma	29.8	VIM, PAX2, CDKN1B, FAS, TP53, PTEN
21	autoimmune thyroiditis	29.7	LGALS3, CD58, IL4, FASLG, FAS, IFNG
22	hodgkin's lymphoma	29.4	PIK3CG, SELP, BCL2, BCR, XIAP, CFLAR
23	alveolar soft part sarcoma	29.3	VIM, MTOR, MSH2, CDH1, MET, TP53
24	paraneoplastic syndromes	29.2	IL2, IL6, PTHLH, CTGF, EGFR, TGFA
25	collecting duct carcinoma	29.1	VIM, VHL, PBRM1, CDKN1B, FLCN, FHIT
26	hepatitis a	29.0	PCNA, BCR, B2M, IL10, IL1B, IL2
27	dna topoisomerase ii	29.0	PCNA, MYC, JUN, CDKN1A, MKI67, GSTP1
28	autoimmune hemolytic anemia	29.0	MYC, IL10, IL2, IL4, IFNA1, IFNA2
29	burkitt's lymphoma	28.9	MYC, BMP6, BCL2, BCL2L11, BCR, BAX
30	hepatitis c	28.9	JUN, IRF1, IL10, IL2, IL4, FAS
31	leiomyomatosis	28.8	VIM, VHL, LDHA, FLCN, FH, TSC1
32	immunodeficiency	28.8	BMP6, BCR, CFLAR, INSR, IL10, IL2
33	goiter	28.7	VHL, VEGFA, PAX8, LGALS3, MET, IL1B
34	mucoepidermoid carcinoma	28.7	PCNA, CDKN1B, MKI67, CTNNA1, NOS2, EGFR
35	hemolytic anemia	28.6	MYC, IL10, IL2, IL4, FASLG, FAS
36	thrombocytosis	28.5	SELP, VEGFA, FLT3, IL1B, IL4, IL6
37	adrenocortical carcinoma	28.5	FGF2, MEN1, FAS, IGF1R, TP53, EGF
38	polymyositis	28.4	VEGFA, VCAM1, MSH2, JUN, IL4, FASLG
39	paraganglioma	28.4	PCNA, VIM, VHL, BCL2, LGALS3, CDKN2A
40	hypothyroidism	28.4	IGFBP3, IFNA1, IFNA2, IFNB1, GHRL, TG
41	prostate carcinoma	28.4	KLF6, VEGFA, BMP6, CDH1, ITGA2, MMP9
42	polycythemia	28.2	PIK3CG, SELP, VHL, VEGFA, BCR, FTH1
43	retinal vein occlusion	28.1	VEGFA, ITGA2, IL10, IL1B, IL4, IL6
44	myasthenia gravis	28.0	BCL2, MMP9, IL10, IL2, IL4, IL6
45	papillary renal cell carcinoma	27.9	PCNA, VHL, VEGFA, PBRM1, KDR, MKI67
46	non-hodgkin lymphoma	27.9	MYC, BCL10, BCL2, BCR, XIAP, B2M
47	angiomyolipoma	27.9	VIM, MYC, PAX8, PAX2, MTOR, CDKN2A
48	breast cancer	27.8	NCOA1, MYC, BMP6, UBC, CDKN1B, CDH1
49	hyperthyroidism	27.7	SELP, PAX8, B2M, INSR, IL4, IL6
50	proteinuria	27.7	SELP, VEGFA, VCAM1, BMP6, BMP7, PAX2

Approved drugs:

Drug clinical trials:

Inferred drug relations via UMLS/NDF-RT:

^43 28 aldesleukin, hydroxyurea, interferon, interferon alfa 2-b, interferon alfa-2a, interferon alfa-2a,recombinant, interferon alfa-2b, interferon alfa-2b,recombinant, interferon alfa-3n,human leukocyte derived, interferon alfacon-1, interferon beta-1a,recombinant, interferon beta-1b,recombinant, interferon gamma-1b, medroxyprogesterone, medroxyprogesterone acetate, peginterferon alfa-2a, peginterferon alfa-2b, thalidomide

MalaCards organs/tissues related to renal carcinoma:

²²

MGI Mouse Phenotypes related to renal carcinoma:

²⁵ (show all 29)

id	Description	MGI Source Accession	Score	Top Affiliating Genes
1	craniofacial phenotype	MP:0005382	10.5	PAX8, L1CAM, MITF, FGFR2, MEN1, FES
2	endocrine/exocrine gland phenotype	MP:0005379	10.2	NCOA1, RBPJ, PAX8, PAX2, CDKN1B, MITF
3	hematopoietic system phenotype	MP:0005397	10.2	KLF6, PCNA, RBPJ, VHL, CLDN7, BCL10
4	liver/biliary system phenotype	MP:0005370	9.9	KLF6, VHL, VEGFA, FTH1, IREB2, MEN1
5	nervous system phenotype	MP:0003631	9.7	NCOA1, RBPJ, SELP, LMNA, MYC, BMP7
6	renal/urinary system phenotype	MP:0005367	9.5	NCOA1, RBPJ, SELP, VHL, LMNA, BMP7
7	other phenotype	MP:0005395	9.5	KDR, CDKN2A, ITGA6, ITGB1, IL2, CTSK
8	reproductive system phenotype	MP:0005389	8.9	KLF6, NCOA1, VHL, VEGFA, LMNA, BMP7
9	no phenotypic analysis	MP:0003012	8.3	PCNA, VEGFA, VCAM1, MYC, PAX8, UBE3A
10	immune system phenotype	MP:0005387	8.3	NCOA1, RBPJ, SELP, VIM, LMNA, RAF1
11	limbs/digits/tail phenotype	MP:0005371	8.1	VHL, VEGFA, LMNA, BMP7, BCL2L11, BAX
12	digestive/alimentary phenotype	MP:0005381	7.7	RBPJ, VHL, VEGFA, LMNA, MYC, BMP7
13	behavior/neurological phenotype	MP:0005386	7.6	NCOA1, RBPJ, SELP, VIM, LMNA, USH1C
14	pigmentation phenotype	MP:0001186	7.5	RBPJ, LMNA, MYC, BMP7, PAX2, BCL2
15	hearing/vestibular/ear phenotype	MP:0005377	7.4	LMNA, MYC, BMP7, USH1C, PAX8, PAX2
16	integument phenotype	MP:0010771	7.3	PIK3CG, KLF6, NCOA1, RBPJ, SELP, VHL
17	adipose tissue phenotype	MP:0005375	7.1	LMNA, MYC, BCL2, MTOR, CDKN1A, CDKN1B
18	growth/size phenotype	MP:0005378	6.6	PIK3CG, KLF6, KLF8, NCOA1, RBPJ, SELP
19	skeleton phenotype	MP:0005390	6.5	PIK3CG, NCOA1, VHL, VEGFA, LMNA, MYC
20	vision/eye phenotype	MP:0005391	5.6	SELP, VIM, VEGFA, LMNA, BMP7, RAF1
21	muscle phenotype	MP:0005369	5.6	PIK3CG, RBPJ, VIM, VHL, VEGFA, LMNA
22	embryogenesis phenotype	MP:0005380	INF	KLF6, KLF8, NCOA1, RBPJ, SETD2, VIM
23	mortality/aging	MP:0010768	INF	KLF6, RBPJ, SELP, SETD2, VHL, VEGFA
24	respiratory system phenotype	MP:0005388	INF	RBPJ, SELP, , LDHA, INSR, GSN
25	homeostasis/metabolism phenotype	MP:0005376	INF	PIK3CG, NCOA1, RBPJ, SELP, SETD2, VIM
26	normal phenotype	MP:0002873	INF	VHL, VEGFA, LMNA, VBP1, MYC, BMP7
27	tumorigenesis	MP:0002006	INF	RBPJ, VHL, MYC, BCL2, LDHA, B2M
28	cellular phenotype	MP:0005384	INF	PIK3CG, KLF6, PCNA, RBPJ, SELP, VIM
29	cardiovascular system phenotype	MP:0005385	INF	PIK3CG, KLF6, RBPJ, SELP, SETD2, VIM

Articles related to renal carcinoma:

(show top 50)    (show all 241)

id	Title	Authors	Year	Affiliating Genes
1	Importance of braina89type fatty acid binding protein f or cell-biological processes in human renal carcinoma cells. (21399875)	TAPlle A.... Stephan C.	2011	FABP7
2	A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. (22012259)	Bertolotto C.... Bressac-de Paillerets B.	2011	MITF
3	The relationship of erythropoietin overexpression wit h von Hippel-Lindau tumour suppressor gene mutations between hypoxia-inducible factor-1I+ and -2I+ in sporadic clear cell renal carcinoma. (21042786)	Gong K.... Na Y.	2010	HIF1A, VHL, EPAS1
4	Expression of FTL and FTH genes encoding ferretin su bunits in lung and renal carcinomas (20088381)	Kudriavtseva A.V.... Senchenko V.N.	2009	FTL, FTH1
5	GTI-2040 displays cooperative anti-tumor activity when combined with interferon alpha against human renal carcinoma xenografts. (19082475)	Vassilakos A.... Young A.	2009	IFNA1
6	Migration of renal carcinoma cells is dependent on protein kinase Cdelta via beta1 integrin and focal adhesion kinase. (18425341)	Brenner W.... Thuroff J.W.	2008	PTK2, PRKCD, ITGB1
7	Hypermethylation of the 5'CpG island of the FHIT gene in clear cell renal carcinomas. (18378390)	Kvasha S.... Vozianov A.F.	2008	FHIT
8	Prognostic role of tumor necrosis, microvessel density, vascular endothelial growth factor and hypoxia inducible factor-1alpha in patients with clear cell renal carcinoma after radical nephrectomy in a long term follow-up. (18547492)	Minardi D.... Muzzonigro G.	2008	VEGFA, HIF1A
9	Somatic mutations of the von Hippel-Lindau disease gene in renal carcinomas occurring in patients with long-term dialysis. (17438007)	Inoue H.... Okuyama A.	2007	VHL
10	Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. (17664477)	Ryan C.W.... Crawford E.D.	2007	RAF1
11	Erythropoietin reduces cisplatin-induced apoptosis in renal carcinoma cells via a PKC dependent pathway. (18075299)	Li J.... Gobe G.	2007	BCL2, CCND1, BAX
12	Induction of Fas (CD95/APO-1) ligand is essential for p53-dependent apoptosis in an in vitro renal carcinoma model system. (17505842)	Okazaki T.... Sakamuro D.	2007	FAS, FASLG
13	Mechanism of reversal of multidrug resistance in human renal carcinoma cells by protein kinase C inhibitor (16750009)	Liu T.... Liu G.F.	2006	PRKCA, ABCB1, DYT10
14	Gene expression analysis of renal carcinoma: adipose differentiation-related protein as a potential diagnostic and prognostic biomarker for clear-cell renal carcinoma. (15682440)	Yao M.... Kubota Y.	2005	NNMT, PLIN1, PLIN2
15	Visualisation of transforming growth factor-beta 1, tissue kallikrein, and kinin and transforming growth factor-beta receptors on human clear-cell renal carcinoma cells. (15899700)	Moodley R.... Bhoola K.D.	2005	TGFB1
16	Renal carcinomas with the t(6;11)(p21;q12): clinicopathologic features and demonstration of the specific alpha-TFEB gene fusion by immunohistochemistry, RT-PCR, and DNA PCR. (15644781)	Argani P.... Ladanyi M.	2005	TFEB
17	A unique case of renal carcinoma with Xp11.2 translocations/ TFE3 gene fusions in a 3-year-old child, with coexistent von Hippel-Lindau gene mutation. (15383938)	Parast M.M.... Shehata B.	2004	VHL
18	The in vitro and in vivo effects of re-expressing methylated von Hippel-Lindau tumor suppressor gene in clear cell renal carcinoma with 5-aza-2'-deoxycytidine. (15501981)	Alleman W.G.... Vasselli J.R.	2004	VEGFA
19	Altered pattern of major histocompatibility complex expression in renal carcinoma: tumor-specific expression of the nonclassical human leukocyte antigen-G molecule is restricted to clear cell carcinoma while up-regulation of other major histocompatibility complex antigens is primarily distributed in all subtypes of renal carcinoma. (12547708)	Ibrahim E.C.... Paul P.	2003	HLA-G
20	Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe FranAsais d'ImmunothAcrapie. (12196373)	NAcgrier S.... Lasset C.	2002	IFNA1
21	Does renal carcinoma affect the expression of P-selectin on platelets? (12382022)	Mantur M.... Wasiluk A.	2002	SELP
22	Enhancement of sensitivity to capecitabine in human renal carcinoma cells transfected with thymidine phosphorylase cDNA. (11291085)	Morita T.... Tokue A.	2001	TYMP
23	CDKNA2A mutation analysis, protein expression, and deletion mapping of chromosome 9p in conventional clear-cell renal carcinomas: evidence for a second tumor suppressor gene proximal to CDKN2A. (11159196)	Schraml P.... Moch H.	2001	CDKN2A
24	Renal carcinoma cell lines inhibit natural killer activity via the CD94 receptor molecule. (11499809)	Stanley A.J.... Patel P.M.	2001	KLRD1
25	SPARC expression in primary human renal cell carcinom a: upregulation of SPARC in sarcomatoid renal carcinoma. (11679940)	Sakai N.... Yao M.	2001	SPARC
26	Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. (11431362)	Wiesener M.S.... Eckardt K.U.	2001	HIF1A, VHL
27	NF-kappa B does not modulate sensitivity of renal carcinoma cells to TNF alpha-related apoptosis-inducing ligand (TRAIL). (11205254)	Pawlowski J.E.... Kraft A.S.	2000	TNFSF10
28	The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. (10454537)	Koochekpour S.... Vande Woude G.F.	1999	HGF
29	Biomodulation of 5-fluorouracil by interferon-alpha in human renal carcinoma cells: relationship to the expression of thymidine phosphorylase. (10412941)	Morita T.... Tokue A.	1999	TYMP, IFNA1
30	Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. (10433944)	Lubensky I.A.... Zbar B.	1999	MET
31	Heterogeneity and susceptibility to apoptosis of human renal carcinoma cells in vitro. (10068906)	Dell'Antonio G.... Manfredi A.A.	1998	EGF
32	Divergent pathways regulate ligand-independent activation of ER alpha in SK-N-BE neuroblastoma and COS-1 renal carcinoma cells. (9626659)	Patrone C.... Maggi A.	1998	HRAS, EFNA5
33	Preoperative subcutaneous immunotherapy with interleukin-2 in renal carcinoma with synchronous metastasis: randomized clinico-biological study. Preoperative use of Il-2 in renal carcinoma (9181906)	Scardino E.... Rocco F.	1997	IL2
34	Sensitization of renal carcinoma to radiation using alpha interferon (IFNA) gene transfection. (9355869)	SyljuAYsen R.G.... McBride W.H.	1997	IFNA1
35	Epidermal growth factor (EGF) increases the in vitro invasion, motility and adhesion interactions of the primary renal carcinoma cell line, A704. (8943684)	Price J.T.... Haites N.E.	1996	EGF
36	A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma. (8781117)	Gaugler B.... Van den Eynde B.J.	1996	MOK
37	Cytokines in combination with chemotherapy for advanced renal carcinoma--the importance of patient selection. (10851510)	Joffe J.K.... Selby P.J.	1996	IL2, IFNA1
38	Integrin expression on cell adhesion function and up-regulation of P125FAK and paxillin in metastatic renal carcinoma cells. (9023046)	Jenq W.... Ramirez G.	1996	PXN, ITGA2
39	Suppression of growth of renal carcinoma cells by the von Hippel-Lindau tumor suppressor gene. (7585510)	Chen F.... Zbar B.	1995	VHL
40	Antiproliferative effects of four different cytokines on renal carcinoma cell lines. (7645950)	Buszello H.	1995	IFNG
41	Role of intercellular adhesion molecule-1 (ICAM-1) and lymphocyte function-associated antigen-1 (LFA-1) in peripheral blood mononuclear cell activation by human renal carcinoma cells. (7879317)	Hansen A.B.... Andersen C.B.	1994	ICAM1
42	Stimulation of intercellular adhesion molecule-1 (ICAM-1) antigen expression and shedding by interferon-gamma and phorbol ester in human renal carcinoma cell cultures: relation to peripheral blood mononuclear cell adhesion. (7974918)	Hansen A.B.... Andersen C.B.	1994	ICAM1, IFNG
43	Integrins and laminins in human renal carcinoma cells and tumors grown in nude mice. (8044804)	Korhonen M.... Virtanen I.	1994	ITGA6, LAMA1
44	Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. (7881415)	Foster K.... Ferguson-Smith M.A.	1994	VHL
45	Human renal carcinoma line transfected with interleukin-2 and/or interferon alpha gene(s): implications for live cancer vaccines. (8423625)	Belldegrun A.... McBride W.H.	1993	IFNA1
46	Humoral hypercalcaemia in renal carcinoma due to parathyroid hormone related protein. (8306145)	Sandhu D.P.... Ratcliffe W.A.	1993	PTHLH
47	Difluoromethylornithine and ethylglyoxal bis(guanylhydrazone) as inhibitors of human renal carcinoma cell proliferation and polyamine metabolism. (8352568)	Sjoholm A.... Nygren P.	1993	ODC1, AMD1
48	Growth regulation of human renal carcinoma cells: role of transforming growth factor alpha. (1596891)	Atlas I.... Kumar R.	1992	EGFR, TGFA
49	Modulation of pro-epidermal growth factor, pro-transforming growth factor alpha and epidermal growth factor receptor gene expression in human renal carcinomas. (2354442)	Petrides P.E.... Jakse G.	1990	EGF, TGFA
50	Human renal carcinoma expresses two messages encoding a parathyroid hormone-like peptide: evidence for the alternative splicing of a single-copy gene. (3290897)	Thiede M.A.... Rodan G.A.	1988	PTHLH

Genes related to renal carcinoma according to GeneCards:

(show top 50)    (show all 258)

id	Symbol	Description	Score	GeneCards Section Context
1	RCA1	renal carcinoma associated 1	11.0	Aliases & Descriptions, Publications
2	MET	met proto-oncogene (hepatocyte growth factor receptor)	11.0	Publications, Functions, Summaries
3	DIRC2	disrupted in renal carcinoma 2	11.0	Transcripts, Publications, Proteins, Aliases & Descriptions (show all 5 sections) Orthologs
4	CA12	carbonic anhydrase XII	11.0	Summaries
5	RNF139	ring finger protein 139	11.0	Aliases & Descriptions
6	DIRC1	disrupted in renal carcinoma 1	11.0	Proteins, Transcripts, Aliases & Descriptions
7	FAM153A	family with sequence similarity 153, member A	11.0	Aliases & Descriptions
8	CCDC34	coiled-coil domain containing 34	11.0	Aliases & Descriptions
9	RPLP2	ribosomal protein, large, P2	11.0	Publications, Aliases & Descriptions
10	FBXO9	F-box protein 9	11.0	Aliases & Descriptions
11	NDUFV3	NADH dehydrogenase (ubiquinone) flavoprotein 3, 10kDa	11.0	Aliases & Descriptions
12	ZSCAN21	zinc finger and SCAN domain containing 21	11.0	Aliases & Descriptions
13	MED6	mediator complex subunit 6	11.0	Aliases & Descriptions
14	ZRSR2	zinc finger (CCCH type), RNA-binding motif and serine/arginine rich 2	11.0	Aliases & Descriptions
15	ZNF839	zinc finger protein 839	11.0	Aliases & Descriptions
16	ECI2	enoyl-CoA delta isomerase 2	11.0	Aliases & Descriptions
17	RLIM	ring finger protein, LIM domain interacting	11.0	Aliases & Descriptions
18	MESDC2	mesoderm development candidate 2	11.0	Aliases & Descriptions
19	PHF11	PHD finger protein 11	11.0	Aliases & Descriptions
20	PLA2G16	phospholipase A2, group XVI	11.0	Aliases & Descriptions
21	DNAJA2	DnaJ (Hsp40) homolog, subfamily A, member 2	11.0	Aliases & Descriptions
22	GCC2	GRIP and coiled-coil domain containing 2	11.0	Aliases & Descriptions
23	AARS	alanyl-tRNA synthetase	11.0	Aliases & Descriptions
24	SCAF11	SR-related CTD-associated factor 11	11.0	Aliases & Descriptions
25	RBM5	RNA binding motif protein 5	11.0	Aliases & Descriptions
26	ST13	suppression of tumorigenicity 13 (colon carcinoma) (Hsp70 interacting protein)	11.0	Aliases & Descriptions
27	STIP1	stress-induced-phosphoprotein 1	11.0	Aliases & Descriptions
28	BRAP	BRCA1 associated protein	11.0	Aliases & Descriptions
29	TP53BP2	tumor protein p53 binding protein, 2	11.0	Aliases & Descriptions
30	IGBP1	immunoglobulin (CD79A) binding protein 1	11.0	Aliases & Descriptions
31	YTHDF2	YTH domain family, member 2	11.0	Aliases & Descriptions
32	LDHB	lactate dehydrogenase B	11.0	Aliases & Descriptions
33	NUB1	negative regulator of ubiquitin-like proteins 1	11.0	Aliases & Descriptions
34	LDHA	lactate dehydrogenase A	11.0	Aliases & Descriptions
35	KCTD3	potassium channel tetramerisation domain containing 3	11.0	Aliases & Descriptions
36	USH1C	Usher syndrome 1C (autosomal recessive, severe)	11.0	Aliases & Descriptions
37	ZC3H14	zinc finger CCCH-type containing 14	11.0	Aliases & Descriptions
38	STX4	syntaxin 4	11.0	Aliases & Descriptions
39	USP32	ubiquitin specific peptidase 32	11.0	Aliases & Descriptions
40	DIRC3	disrupted in renal carcinoma 3	11.0	Transcripts, Aliases & Descriptions
41	KIF21A	kinesin family member 21A	11.0	Aliases & Descriptions
42	RABEP1	rabaptin, RAB GTPase binding effector protein 1	11.0	Aliases & Descriptions
43	ROCK1	Rho-associated, coiled-coil containing protein kinase 1	11.0	Aliases & Descriptions
44	ZNF608	zinc finger protein 608	11.0	Aliases & Descriptions
45	RBPJ	recombination signal binding protein for immunoglobulin kappa J region	11.0	Aliases & Descriptions
46	PRPF40A	PRP40 pre-mRNA processing factor 40 homolog A (S. cerevisiae)	11.0	Aliases & Descriptions
47	IRAK4	interleukin-1 receptor-associated kinase 4	11.0	Aliases & Descriptions
48	STK11	serine/threonine kinase 11	11.0	Aliases & Descriptions
49	PFKFB3	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	11.0	Aliases & Descriptions
50	PPP2R5C	protein phosphatase 2, regulatory subunit B', gamma	11.0	Aliases & Descriptions

Pathways related to renal carcinoma according to GeneDecks:

(show top 50)    (show all 271)

id	Pathway	Score	Top Affiliating Genes
1	Signal transduction_PTEN pathway41	10.8	PCNA, ITGB1, IGF1R, TSC2, PXN
2	Actin-Based Motility by Rho Family GTPases36	10.6	BMP7, ITGA6, GSN, IL2, IGF1, CTGF
3	Renal cell carcinoma20	10.5	VHL, RAF1, JUN, FH, MET, HRAS
4	eNOS Signaling36	10.1	BMP6, BMP7, FLT3, INSR, FGFR2, MET
5	Breast Cancer Regulation by Stathmin136	10.0	BMP7, RAF1, FGF2, FGFR2, IGF1R, TP53BP2
6	CREB Pathway36	10.0	BMP6, BMP7, KDR, FGFR2, IL2, IGF1R
7	Signal transduction_AKT signaling41	9.9	PCNA, MYC, BCL2L11, BAX, MTOR, CDKN1A
8	Akt Signaling36	9.8	PIK3CG, BMP7, RAF1, ITGA1, ITGA2, ITGA6
9	Paxillin Interactions36	9.7	KDR, ITGA1, ITGA2, ITGA6, ITGB1, FLT3
10	mTOR Pathway36	9.6	BMP6, BMP7, INSR, FGF2, IL2, IL6
11	Glioblastoma Multiforme36	9.5	RAF1, CDKN1A, CDKN1B, MAPK1, IGF1R, HRAS
12	PPAR Pathway36	9.3	NCOA1, RAF1, ITGA1, ITGA2, ITGA6, ITGB1
13	14-3-3 Induced Intracellular Signaling36	9.3	BMP7, RAF1, JUN, FLT3, INSR, FGF2
14	Signal transduction PTEN pathway10	9.2	PCNA, RAF1, MTOR, JUN, CDKN1A, ITGB1
15	Activation of cAMP-Dependent PKA36	9.1	BMP7, RAF1, CLCNKB, KDR, KCTD3, FLT3
16	PTEN Pathway36	9.1	BMP7, KDR, LAMA1, ITGA1, ITGA2, ITGA6
17	Ras Pathway36	9.1	BMP7, RAF1, KDR, JUN, ITGA1, ITGA2
18	ILK Signaling36	9.0	VIM, BMP7, LIMS1, KDR, LAMA1, JUN
19	Rac1 Pathway36	8.8	BMP6, BMP7, RAF1, KDR, JUN, ITGA1
20	JNK Pathway36	8.7	BMP6, BMP7, RAF1, KDR, BCL2, BAX
21	Telomerase Components in Cell Signaling36	8.7	MYC, BMP6, BMP7, KDR, FGF2, FGFR2
22	Cytokine-cytokine receptor interaction20	8.6	VEGFA, BMP7, KDR, FLT3, MET, IL10
23	p70S6K Signaling36	8.6	BMP6, BMP7, RAF1, KDR, INSR, FGF2
24	Glioma20	8.6	PIK3CG, RAF1, MTOR, CDKN1A, CDKN2A, MAPK1
25	Focal adhesion20	8.5	PIK3CG, RAF1, KDR, BCL2, LAMA1, XIAP
26	Nanog in Mammalian ESC Pluripotency36	8.4	BMP6, BMP7, RAF1, KDR, FLT3, INSR
27	Signaling Involved in Cardiac Hypertrophy36	8.3	RAF1, JUN, ITGA1, ITGA2, ITGA6, ITGB1
28	Estrogen Pathway36	8.2	NCOA1, BMP6, BMP7, RAF1, KDR, BCL2
29	GPCR Pathway36	8.2	BMP6, BMP7, RAF1, KDR, BCL10, JUN
30	Bladder cancer20	8.2	VEGFA, MYC, RAF1, CDKN1A, CDKN2A, CDH1
31	Prostate cancer20	8.2	PIK3CG, RAF1, BCL2, MTOR, CDKN1A, CDKN1B
32	Rap1 Pathway36	8.2	BMP6, BMP7, RAF1, ITGA1, ITGA2, ITGA6
33	Renin-Angiotensin Pathway36	8.1	VCAM1, BMP6, BMP7, RAF1, KDR, JUN
34	p53 Mediated Apoptosis36	8.1	BMP6, BMP7, KDR, BCL2, BAX, FGF2
35	ERK Signaling36	8.1	MYC, BMP6, BMP7, RAF1, LAMA1, ITGA1
36	Endothelin-1 Signaling Pathway36	8.1	MYC, BMP6, BMP7, RAF1, FLT3, INSR
37	Cellular Apoptosis Pathway36	8.0	BMP6, BMP7, KDR, BCL2, BCL2L11, BAX
38	PAK Pathway36	8.0	BMP6, BMP7, KDR, BCL2, BAX, FGF2
39	Mitochondrial Apoptosis36	7.9	BMP6, BMP7, KDR, BCL2, BCL2L11, BAX
40	Rho Family GTPases36	7.9	VIM, BMP6, BMP7, RAF1, KDR, BCL2
41	Melanoma20	7.8	PIK3CG, RAF1, CDKN1A, CDKN2A, CDH1, MITF
42	p38 Signaling36	7.4	BMP6, BMP7, KDR, BCL2, BAX, IRAK4
43	Tec Kinases Signaling36	7.4	BMP6, BMP7, BCL2, BAX, ITGA1, ITGA2
44	Pancreatic Adenocarcinoma36	7.4	BMP6, BMP7, RAF1, KDR, BCL2, CDKN1A
45	MAPK Family Pathway36	7.4	BMP6, BMP7, RAF1, KDR, BCL2, BAX
46	Antioxidant Action of Vitamin-C36	7.3	BMP6, BMP7, KDR, BCL2, BAX, JUN
47	TGF-Beta Pathway36	7.3	BMP6, BMP7, KDR, BCL2, BAX, JUN
48	Molecular Mechanisms of Cancer36	6.4	PIK3CG, MYC, BMP6, BMP7, RAF1, KDR
49	JAK-STAT Pathway36	6.1	MYC, BMP6, BMP7, RAF1, KDR, BCL2
50	Pathways in cancer20	5.3	PIK3CG, VEGFA, MYC, PAX8, BCL2, BCR

Compounds related to renal carcinoma according to GeneDecks:

(show top 50)    (show all 457)

id	Compound	Score	Top Affiliating Genes
1	glucose32	11.5	SETD2, VHL, BMP7, LDHA, LDHB, BAIAP2L1
2	threonine32	10.8	RAF1, PAX8, PAX2, BAIAP2L1, CDKN1B, IRAK4
3	cyclophosphamide32 34 9 9	13.7	NPPB
4	calcium32 9 18 9	13.5	VHL, LMNA, BMP7, CLCNKB, BCR, LGALS3
5	heparin32 9 18 9	13.1	PIK3CG, VIM, RAF1, LGALS3, LAMA1, CDH1
6	pge232	9.7	SETD2, VCAM1, BMP7, RAF1, CDH1, IRF1
7	bleomycin32 9 9	11.5	GSTM1, GSTP1, FGF2, IL4, IGF1, IFNA1
8	polysaccharide32	9.5	SELP, VCAM1, BMP6, KDR, LGALS3, B2M
9	forskolin32 42 9 9	12.4	VIM, BMP6, RAF1, PAX8, JUN, CDKN1B
10	ribonucleic acid32	9.4	KLF6, MYC, BMP6, BMP7, PAX8, MMP9
11	cholesterol32 9 18 9	12.2	NCOA1, SELP, VCAM1, LMNA, BCR, B2M
12	bromodeoxyuridine32	9.2	PCNA, VIM, MYC, BMP6, BMP7, CDKN1A
13	noxa32	9.1	BCL2, BCL2L11, BAX, XIAP, CFLAR, CDKN1A
14	ang ii32	9.1	PIK3CG, VEGFA, ENPEP, ANPEP, MAPK1, DYT10
15	lipid32	9.1	PIK3CG, NCOA1, SETD2, VIM, VCAM1, LMNA
16	erlotinib32 34 9 9	12.0	VEGFA, KDR, MTOR, CDKN1B, CDH1, MAPK1
17	azathioprine32 34 9 9	12.0	PCNA, VIM, CDKN2A, CDH1, GSN, GSTP1
18	dutp32	8.9	PCNA, BCL2, LGALS3, BAX, XIAP, CFLAR
19	ifn-alpha32	8.8	CDKN2A, IRF1, IL10, IL2, IL6, FASLG
20	progesterone32 42 9 18 9	12.8	NCOA1, PCNA, SETD2, BMP7, BCL2, CDKN1A
21	taxane32	8.8	VEGFA, KDR, BCL2, MTOR, CDKN1A, TP53
22	carboplatin32 34 9 9	11.7	VEGFA, KDR, BCL2, XIAP, MSH2, FASLG
23	estrogen32	8.7	KLF6, NCOA1, PCNA, SETD2, VHL, BMP7
24	thapsigargin32 42	9.6	PIK3CG, PCNA, RAF1, BCL2, BCR, IL2
25	prednisolone32 9 9	10.6	VCAM1, MYC, BMP6, GSTM1, FGF2, IL10
26	depsipeptide32	8.6	MYC, RAF1, BCL2, BCL2L11, BAX, CFLAR
27	gf 109203x32 42	9.5	PIK3CG, VEGFA, RAF1, JUN, CDKN1A, FGF2
28	flavopiridol32 9 9	10.5	PIK3CG, VEGFA, BCL2, BAX, XIAP, CFLAR
29	tgf beta132	8.5	SETD2, VCAM1, BMP6, BMP7, KDR, CDKN1A
30	5-aza-2deoxycytidine32	8.3	PCNA, VIM, VHL, MYC, BMP6, XAF1
31	ciglitazone32	8.2	BAX, JUN, CDKN1A, CDKN1B, MMP9, IL1B
32	gefitinib32 34 9 9	11.1	PIK3CG, SELP, VIM, VEGFA, KDR, MTOR
33	suberoylanilide hydroxamic acid32	8.1	MYC, RAF1, BCL2, BCL2L11, BAX, XIAP
34	indomethacin32 9 9	10.0	NCOA1, PCNA, VIM, MYC, BMP6, RAF1
35	triptolide32	8.0	VEGFA, BCL2, BAX, JUN, IL1B, IL2
36	pdtc32	7.4	PIK3CG, SETD2, VCAM1, RAF1, BCL2, XIAP
37	doxorubicin32 34 9 9	10.2	PIK3CG, SETD2, VIM, BMP6, RAF1, KDR
38	resveratrol32 9 18 9	10.2	PIK3CG, PCNA, VEGFA, RAF1, BCL2, BAX
39	wortmannin32 42	8.1	PIK3CG, SETD2, VIM, VCAM1, RAF1, KDR
40	herbimycin a32 42	8.1	PIK3CG, VCAM1, MYC, BMP6, RAF1, JUN
41	cyclosporin a32 42	8.0	PIK3CG, SELP, MYC, RAF1, MTOR, B2M
42	gemcitabine32 34 9 9	10.0	PCNA, VEGFA, MYC, KDR, BCL2, BAX
43	retinoic acid32 42 18	8.8	PIK3CG, NCOA1, SELP, SETD2, VCAM1, LMNA
44	butyrate32	6.7	NCOA1, PCNA, SETD2, VIM, MYC, BMP6
45	paclitaxel32 34 9 9	8.3	PIK3CG, PCNA, SETD2, VIM, VEGFA, MYC
46	dexamethasone32 42 34 9 9	8.7	PCNA, SELP, VIM, VEGFA, VCAM1, MYC
47	genistein32 9 18 9	7.6	PIK3CG, NCOA1, PCNA, SELP, SETD2, VIM
48	adriamycin32	INF	VIM, MYC, BCL2, BAX, XIAP, B2M
49	h2o232	INF	PIK3CG, BCL2L11, BCR, LGALS3, BAIAP2L1, FTH1
50	ascorbic acid32 18	INF	PIK3CG, PCNA, SETD2, BMP7, RAF1, FTH1

Cellular components related to renal carcinoma according to GeneDecks:

(show all 12)

id	Name	GO ID	Score	Top Affiliating Genes
1	cytoplasm	GO:005737	INF	PTEN, TGFB1, TFE3, TFEB, PVALB, STAT3
2	external side of plasma membrane	GO:009897	10.0	ANXA5, ANPEP, IFNG, ICAM1, CTSB, TGFBR3
3	perinuclear region of cytoplasm	GO:048471	9.7	CTSB, PLA2G16, NOS2, NF2, EGFR, TSC2
4	cell surface	GO:009986	9.6	CRYAB, TGFA, TGFB1, TGFBR3, DPP4, ADAM17
5	membrane	GO:016020	9.4	TSC2, INSR, SLC2A1, PIK3CG, GCC2, VHL
6	protein complex	GO:043234	8.6	PAX2, CDKN2A, MMP9, MITF, BCL10, MEN1
7	extracellular region	GO:005576	8.2	TGFB1, DPP4, TG, CXCL12, NPPA, NPPB
8	plasma membrane	GO:005886	8.0	PLIN2, NF2, PDS5A, KLKB1, KLRD1, EGF
9	cytosol	GO:005829	7.6	BCL2L11, BCR, LDHA, LDHB, UBE3A, UBC
10	extracellular space	GO:005615	7.4	SPARC, IL24, IL2, IL1B, IL10, MET
11	nucleoplasm	GO:005654	INF	CDKN1B, EP300, POU5F1, , PRKCA, EPAS1
12	nucleus	GO:005634	INF	TP53, CRYAB, CCND3, MAPK1, FAS, FASLG

Biological processes related to renal carcinoma according to GeneDecks:

(show top 50)    (show all 65)

id	Name	GO ID	Score	Top Affiliating Genes
1	small molecule metabolic process	GO:044281	10.7	LDHB, CA12, LDHA, NCOA1, PIK3CG, AMD1
2	response to wounding	GO:009611	10.6	POU5F1, MET, TGFB1, F2R, CTSB, CTGF
3	negative regulation of protein phosphorylation	GO:001933	10.5	INSR, CACTIN, TGFB1, PTEN, IGFBP3, FAM129A
4	cellular response to stress	GO:033554	10.4	EPO, VEGFA, VHL, EPAS1, UBC, AQP1
5	regulation of transcription from RNA polymerase II promoter in response to hypoxia	GO:061418	10.3	EPO, EPAS1, EP300, CA9, UBC, VEGFA
6	cellular component disassembly involved in apoptotic process	GO:006921	10.3	PRKCD, VIM, LMNA, CDH1, GSN, PTK2
7	cGMP biosynthetic process	GO:006182	10.3	NPPA, NPPB, NPR1, NPPC, AQP1
8	positive regulation of protein phosphorylation	GO:001934	10.1	GNB2L1, CCND3, FAM129A, IL1B, INSR, MTOR
9	positive regulation of cell migration	GO:030335	10.1	KDR, ITGB1, INSR, CCL26, F2R, GNB2L1
10	cellular response to hypoxia	GO:071456	10.1	EPAS1, AQP1, EPO, LMNA, EP300, BMP7
11	positive regulation of phosphatidylinositol 3-kinase cascade	GO:014068	10.1	UBE3A, PTK2, F2R, IGF1, FLT3, KDR
12	axon guidance	GO:007411	10.0	MET, EGFR, STIP1, HRAS, ROCK1, EPHB2
13	B cell differentiation	GO:030183	10.0	IL10, FLT3, IL4, ADAM17, ITGB1, MSH2
14	positive regulation of apoptotic process	GO:043065	10.0	RBM5, TP53, GNB2L1, ITGA6, FAS, FASLG
15	aging	GO:007568	9.9	VCAM1, GSN, PTH1R, FAS, CRYAB, TGFB1
16	positive regulation of MAPK cascade	GO:043410	9.9	FGFR2, HRAS, F2R, IGFBP3, FLT3, ITGB1
17	positive regulation of osteoblast differentiation	GO:045669	9.9	NPPC, CYR61, IGF1, IL6, MEN1, BMP7
18	activation of cysteine-type endopeptidase activity involved in apoptotic process	GO:006919	9.9	TNFSF10, MYC, BAX, BCL2L11, CDKN1B, FASLG
19	positive regulation of endothelial cell proliferation	GO:001938	9.9	MTOR, BMP6, VEGFA, HIF1A, KDR, CCL26
20	induction of apoptosis	GO:006917	9.8	TP53BP2, FASLG, FAS, MAPK1, TGFB1, PTEN
21	cell cycle arrest	GO:007050	9.7	IFNG, STK11, TGFB1, MYC, MSH2, CDKN1A
22	response to organic cyclic compound	GO:014070	9.7	MET, CDKN1A, PRKCA, IL4, CCND1, ICAM1
23	positive regulation of DNA replication	GO:045740	9.6	MET, EPO, EGFR, HRAS, IGF1R, IGF1
24	response to ethanol	GO:045471	9.6	MMP9, BCL2, GSN, IL4, CCND1, ICAM1
25	positive regulation of epithelial cell proliferation	GO:050679	9.6	PAX2, IGF1, FGFR2, BMP6, EGFR, TGFA
26	angiogenesis	GO:001525	9.6	ENPEP, ANPEP, FGFR2, JUN, KDR, VEGFA
27	activation of MAPK activity	GO:000187	9.6	INSR, UBC, FGF2, MET, HGF, CXCR4
28	response to estradiol stimulus	GO:032355	9.6	INSR, MMP9, NCOA1, PRKCA, STAT3, TGFB1
29	MAPK cascade	GO:000165	9.6	MYC, TGFB1, RAF1, BRAP, MEN1, TGFA
30	cytokine-mediated signaling pathway	GO:019221	9.6	XAF1, IRAK4, VCAM1, IFNG, HLA-G, IRF1
31	signal transduction	GO:007165	9.5	SPARC, PPP2R5C, EGF, TNFSF10, TP53BP2, HRAS
32	negative regulation of cell growth	GO:030308	9.5	NPPB, NPR1, STK11, CDKN1A, CRYAB, TGFB1
33	negative regulation of neuron apoptotic process	GO:043524	9.4	BCL2, JUN, F2R, HRAS, HIF1A, SOD2
34	platelet activation	GO:030168	9.3	F2RL2, IL6, RAF1, VEGFA, SELP, PIK3CG
35	activation of pro-apoptotic gene products	GO:008633	9.3	FASLG, TNFSF10, FAS, BAX, BCL2L11, BCL2
36	fibroblast growth factor receptor signaling pathway	GO:008543	9.3	RAF1, UBC, MTOR, CDKN1B, FGF2, PRKCA
37	induction of apoptosis by intracellular signals	GO:008629	9.2	BCL2, XIAP, PRKCA, TP53, CASP3, BCL2L11
38	epidermal growth factor receptor signaling pathway	GO:007173	9.1	PRKAR1A, PTEN, TGFA, TSC2, EGFR, EGF
39	blood coagulation	GO:007596	9.0	ANXA5, MAPK1, PIK3CG, SELP, IGF1, VEGFA
40	nerve growth factor receptor signaling pathway	GO:048011	9.0	RAF1, PRKAR1A, PRKCD, TSC2, PRKCA, ADAM17
41	response to hypoxia	GO:001666	8.9	NPPC, ADAM17, EP300, EPAS1, NPPB, CXCR4
42	anti-apoptosis	GO:006916	8.9	IL10, EPO, VHL, PAX2, BCL2, CFLAR
43	release of cytochrome c from mitochondria	GO:001836	8.9	BCL2, BAX, MYC, CASP3, TP53, SOD2
44	positive regulation of cell proliferation	GO:008284	8.7	FASLG, IL6, IL2, FGFR2, FGF2, INSR
45	negative regulation of apoptotic process	GO:043066	8.0	PIK3CG, VEGFA, MYC, RAF1, PAX2, KDR
46	response to drug	GO:042493	8.0	ABCB1, MYC, PLIN2, NNMT, ABCC1, ABCG2
47	apoptotic process	GO:006915	7.9	EPO, EP300, EFNA5, ROCK1, CXCR4, IFNG
48	positive regulation of transcription from RNA polymerase II promoter	GO:045944	7.4	KLF6, NCOA1, RBPJ, VEGFA, MYC, BMP6
49	positive regulation of transcription, DNA-dependent	GO:045893	7.2	IGF1, IL4, IL10, IL1B, IL6, F2R
50	negative regulation of cell proliferation	GO:008285	INF	VHL, RBM5, RAF1, NME1, NPPC, SOD2

Molecular functions related to renal carcinoma according to GeneDecks:

(show all 13)

id	Name	GO ID	Score	Top Affiliating Genes
1	protein binding	GO:005515	INF	SMAD2, HPRT1, HRAS, CACTIN, CASP3, HSP90AA1
2	integrin binding	GO:005178	10.3	ADAM17, IGF1, VCAM1, KDR, ITGA1, CTGF
3	protein tyrosine kinase activity	GO:004713	10.3	IGF1R, FES, KDR, MET, FGFR2, BCR
4	receptor binding	GO:005102	10.1	NOS2, TNFSF10, HLA-G, GNB2L1, AMACR, FASLG
5	identical protein binding	GO:042802	9.4	ST13, RAF1, CLDN7, BCL2, LDHB, NME1
6	ATP binding	GO:005524	9.4	STK11, PRKCD, PRKCA, NPR1, NME1, ROCK1
7	enzyme binding	GO:019899	9.3	PTEN, PRKCA, PRKCD, TGFB1, HIF1A, NCOA1
8	cytokine activity	GO:005125	9.3	TNFSF10, IFNG, IFNB1, BMP6, IFNA2, FASLG
9	protein kinase binding	GO:019901	9.2	NPR1, VIM, BCL10, MSH2, ITGB1, CCND3
10	protein homodimerization activity	GO:042803	9.0	GSTM3, BAX, VEGFA, RABEP1, CRP, CRYAB
11	transcription factor binding	GO:008134	9.0	VHL, MYC, BCL10, BCL2, JUN, EPAS1
12	protein heterodimerization activity	GO:046982	8.9	TP53, EGFR, HIF1A, EPAS1, TGFB1, TFEB
13	growth factor activity	GO:008083	8.9	EGF, TYMP, TGFA, CXCL12, VEGFA, HGF